Advertisement

Tumor Biology

, Volume 36, Issue 4, pp 2641–2649 | Cite as

MicroRNA-145 as ideal biomarker for the diagnosis of various carcinomas

  • Yanmei Hou
  • Xiang Wang
  • Yan Chen
  • Shengqun Mu
Research Article

Abstract

Increasing evidences indicated that microRNAs (miRNAs) can serve as a noninvasive biomarker with a high sensitivity and specificity for the early diagnosis of various cancers, among which, microRNA-145 (miRNA-145, miR-145) was verified to have strong relationship to irregular apoptosis, thus making it useful in the early detection of cancers. However, contradictory results on its diagnostic accuracy and reliability are still existed in individual studies. Therefore, we conducted this meta-analysis of the relevant published literatures to systematically evaluate the diagnostic value of miR-145 in the prediction of cancers. The sensitivity and specificity of the included studies were used to construct the summary receiver operator characteristic (SROC) curve and calculate the area under the SROC curve (AUC). All analyses were performed using the STATA 12.0 software. Thirteen studies from nine articles were involved in our meta-analysis. The pooled parameters calculated from all studies are as follows: sensitivity, 0.71 (95 % confidence interval (CI) 0.59–0.81); specificity, 0.75 (95 % CI 0.66–0.83); positive likelihood ratio (PLR), 2.9 (95 % CI 1.9–4.4); negative likelihood ratio (NLR), 0.38 (95 % CI 0.25–0.58); and diagnostic odds ratio (DOR), 8 (95 % CI 3–17). In addition, subgroup analyses based on ethnicity suggested that miR-145 as a biomarker on the detection of cancers for Caucasian population showed a higher sensitivity and specificity than for Asian population. In conclusion, the current meta-analysis showed that miR-145 holds a high accuracy in distinguishing cancer patients from healthy controls with noninvasiveness and high efficiency. However, large-scale prospective studies and additional improvements are urgently needed to confirm our findings and its utilization for routine clinical diagnosis in future.

Keywords

MicroRNA-145 Cancer Diagnostic value Meta-analysis 

Notes

Conflicts of interest

None

References

  1. 1.
    Ferlay J, Shin HR, Bray F, Forman D, Mathers C, et al. Estimates of worldwide burden of cancer in 2008: Globocan 2008. Int J Cancer. 2010;127:2893–917.CrossRefPubMedGoogle Scholar
  2. 2.
    Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64:9–29.CrossRefPubMedGoogle Scholar
  3. 3.
    Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.CrossRefPubMedGoogle Scholar
  4. 4.
    Leone G, Fianchi L, Pagano L, Voso MT. Incidence and susceptibility to therapy-related myeloid neoplasms. Chem Biol Interact. 2010;184:39–45.CrossRefPubMedGoogle Scholar
  5. 5.
    Morse MA, Stoner GD. Cancer chemoprevention: principles and prospects. Carcinogenesis. 1993;14:1737–46.CrossRefPubMedGoogle Scholar
  6. 6.
    Zen K, Zhang CY. Circulating microRNAs: a novel class of biomarkers to diagnose and monitor human cancers. Med Res Rev. 2012;32:326–48.CrossRefPubMedGoogle Scholar
  7. 7.
    Mazzone P, Jain P, Arroliga AC, Matthay RA. Bronchoscopy and needle biopsy techniques for diagnosis and staging of lung cancer. Clin Chest Med. 2002;23:137–58. ix.CrossRefPubMedGoogle Scholar
  8. 8.
    Gohagan JK, Marcus PM, Fagerstrom RM, Pinsky PF, Kramer BS, et al. Final results of the lung screening study, a randomized feasibility study of spiral ct versus chest x-ray screening for lung cancer. Lung Cancer. 2005;47:9–15.CrossRefPubMedGoogle Scholar
  9. 9.
    Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011;365:395–409.CrossRefPubMedGoogle Scholar
  10. 10.
    Oken MM, Marcus PM, Hu P, Beck TM, Hocking W, et al. Baseline chest radiograph for lung cancer detection in the randomized prostate, lung, colorectal and ovarian cancer screening trial. J Natl Cancer Inst. 2005;97:1832–9.CrossRefPubMedGoogle Scholar
  11. 11.
    Taplin S, Abraham L, Barlow WE, Fenton JJ, Berns EA, et al. Mammography facility characteristics associated with interpretive accuracy of screening mammography. J Natl Cancer Inst. 2008;100:876–87.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Brenner H, Chang-Claude J, Jansen L, Knebel P, Stock C, et al. Reduced risk of colorectal cancer up to 10 years after screening, surveillance, or diagnostic colonoscopy. Gastroenterology. 2014;146:709–17.CrossRefPubMedGoogle Scholar
  13. 13.
    Takahashi S, Hirayama M, Kuroiwa G, Kawano Y, Takada K, et al. Diagnostic validity of CT gastrography versus gastroscopy for primary lesions in gastric cancer: evaluating the response to chemotherapy, a retrospective analysis. Gastric Cancer. 2013;16:543–8.CrossRefPubMedGoogle Scholar
  14. 14.
    Henschke CI, Yankelevitz DF, Libby DM, Pasmantier MW, Smith JP, et al. Survival of patients with stage i lung cancer detected on ct screening. N Engl J Med. 2006;355:1763–71.CrossRefPubMedGoogle Scholar
  15. 15.
    Mascalchi M, Belli G, Zappa M, Picozzi G, Falchini M, et al. Risk-benefit analysis of x-ray exposure associated with lung cancer screening in the Italung-ct trial. AJR Am J Roentgenol. 2006;187:421–9.CrossRefPubMedGoogle Scholar
  16. 16.
    Rifai N, Gillette MA, Carr SA. Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nat Biotechnol. 2006;24:971–83.CrossRefPubMedGoogle Scholar
  17. 17.
    Etzioni R, Kooperberg C, Pepe M, Smith R, Gann PH. Combining biomarkers to detect disease with application to prostate cancer. Biostatistics. 2003;4:523–38.CrossRefPubMedGoogle Scholar
  18. 18.
    Fiorucci G, Chiantore MV, Mangino G, Percario ZA, Affabris E, et al. Cancer regulator microRNA: potential relevance in diagnosis, prognosis and treatment of cancer. Curr Med Chem. 2012;19:461–74.CrossRefPubMedGoogle Scholar
  19. 19.
    Anindo MI, Yaqinuddin A. Insights into the potential use of microRNAs as biomarker in cancer. Int J Surg. 2012;10:443–9.CrossRefPubMedGoogle Scholar
  20. 20.
    Brase JC, Wuttig D, Kuner R, Sultmann H. Serum microRNAs as non-invasive biomarkers for cancer. Mol Cancer. 2010;9:306.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Madhavan D, Cuk K, Burwinkel B, Yang R. Cancer diagnosis and prognosis decoded by blood-based circulating microRNA signatures. Front Genet. 2013;4:116.PubMedPubMedCentralGoogle Scholar
  22. 22.
    Weiland M, Gao XH, Zhou L, Mi QS. Small RNAs have a large impact: circulating microRNAs as biomarkers for human diseases. RNA Biol. 2012;9:850–9.CrossRefPubMedGoogle Scholar
  23. 23.
    Fabbri M. MiRNAs as molecular biomarkers of cancer. Expert Rev Mol Diagn. 2010;10:435–44.CrossRefPubMedGoogle Scholar
  24. 24.
    George GP, Mittal RD. MicroRNAs: potential biomarkers in cancer. Indian J Clin Biochem. 2010;25:4–14.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Bartels CL, Tsongalis GJ. MicroRNAs: novel biomarkers for human cancer. Clin Chem. 2009;55:623–31.CrossRefPubMedGoogle Scholar
  26. 26.
    Yun SJ, Jeong P, Kim WT, Kim TH, Lee YS, et al. Cell-free microRNAs in urine as diagnostic and prognostic biomarkers of bladder cancer. Int J Oncol. 2012;41:1871–8.PubMedGoogle Scholar
  27. 27.
    Mar-Aguilar F, Mendoza-Ramirez JA, Malagon-Santiago I, Espino-Silva PK, Santuario-Facio SK, et al. Serum circulating microRNA profiling for identification of potential breast cancer biomarkers. Dis Markers. 2013;34:163–9.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Tang D, Shen Y, Wang M, Yang R, Wang Z, et al. Identification of plasma microRNAs as novel noninvasive biomarkers for early detection of lung cancer. Eur J Cancer Prev. 2013;22:540–8.CrossRefPubMedGoogle Scholar
  29. 29.
    Leeflang MM, Deeks JJ, Gatsonis C, Bossuyt PM. Systematic reviews of diagnostic test accuracy. Ann Intern Med. 2008;149:889–97.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Ichimi T, Enokida H, Okuno Y, Kunimoto R, Chiyomaru T, et al. Identification of novel microRNA targets based on microRNA signatures in bladder cancer. Int J Cancer. 2009;125:345–52.CrossRefPubMedGoogle Scholar
  31. 31.
    Luo X, Stock C, Burwinkel B, Brenner H. Identification and evaluation of plasma microRNAs for early detection of colorectal cancer. PLoS ONE. 2013;8:e62880.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Shigehara K, Yokomuro S, Ishibashi O, Mizuguchi Y, Arima Y, et al. Real-time PCR-based analysis of the human bile microRNAome identifies mir-9 as a potential diagnostic biomarker for biliary tract cancer. PLoS One. 2011;6:e23584.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Wach S, Nolte E, Szczyrba J, Stohr R, Hartmann A, et al. MicroRNA profiles of prostate carcinoma detected by multiplatform microRNA screening. Int J Cancer. 2012;130:611–21.CrossRefPubMedGoogle Scholar
  34. 34.
    Zaravinos A, Radojicic J, Lambrou GI, Volanis D, Delakas D, et al. Expression of miRNAs involved in angiogenesis, tumor cell proliferation, tumor suppressor inhibition, epithelial-mesenchymal transition and activation of metastasis in bladder cancer. J Urol. 2012;188:615–23.CrossRefPubMedGoogle Scholar
  35. 35.
    Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 2011;155:529–36.CrossRefPubMedGoogle Scholar
  36. 36.
    Deeks JJ, Macaskill P, Irwig L. The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed. J Clin Epidemiol. 2005;58:882–93.CrossRefPubMedGoogle Scholar
  37. 37.
    Glas AS, Lijmer JG, Prins MH, Bonsel GJ, Bossuyt PM. The diagnostic odds ratio: a single indicator of test performance. J Clin Epidemiol. 2003;56:1129–35.CrossRefPubMedGoogle Scholar
  38. 38.
    Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–60.CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Jackson D, White IR, Thompson SG. Extending DerSimonian and Laird’s methodology to perform multivariate random effects meta-analyses. Stat Med. 2010;29:1282–97.CrossRefPubMedGoogle Scholar
  40. 40.
    Paranjape T, Slack FJ, Weidhaas JB. MicroRNAs: tools for cancer diagnostics. Gut. 2009;58:1546–54.CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Cho WC. OncomiRs: the discovery and progress of microRNAs in cancers. Mol Cancer. 2007;6:60.CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116:281–97.CrossRefPubMedGoogle Scholar
  43. 43.
    Esquela-Kerscher A, Slack FJ. Oncomirs—microRNAs with a role in cancer. Nat Rev Cancer. 2006;6:259–69.CrossRefPubMedGoogle Scholar
  44. 44.
    Stengel D, Bauwens K, Sehouli J, Ekkernkamp A, Porzsolt F. A likelihood ratio approach to meta-analysis of diagnostic studies. J Med Screen. 2003;10:47–51.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2014

Authors and Affiliations

  1. 1.Department Gynaecology and ObstetricsJinan Women and Children Health HospitalJinanChina

Personalised recommendations